Loading...
XJPX
4564
Market cap45mUSD
Dec 05, Last price  
21.00JPY
1D
-4.55%
1Q
-27.59%
Jan 2017
-92.19%
IPO
-95.53%
Name

OncoTherapy Science Inc

Chart & Performance

D1W1MN
XJPX:4564 chart
P/E
—
P/S
9.48
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.88%
Rev. gr., 5y
18.86%
Revenues
750m
+22.93%
1,164,764,000804,491,0001,972,835,0003,327,575,0005,257,628,0005,361,397,0006,223,947,0003,277,411,0001,017,769,000769,956,000266,903,000286,667,000211,251,000280,586,000316,215,000332,477,0001,153,663,0001,134,903,000610,118,000750,048,000
Net income
-815m
L-36.71%
-525,700,000-1,323,362,000-202,073,000148,249,000510,159,000566,758,000726,961,000-1,103,203,000-3,676,647,000-1,334,890,000-2,788,819,000-3,002,063,000-2,851,092,000-2,934,960,000-2,238,558,000-1,561,636,000-2,571,541,000-1,118,644,000-1,288,138,000-815,285,000
CFO
-815m
L-33.63%
-550,898,000-1,091,497,000346,225,000-223,504,0001,024,616,000440,961,000-91,325,000-455,654,000-1,649,667,000-1,702,607,000-2,898,286,000-2,988,040,000-3,035,947,000-2,373,427,000-2,275,529,000-1,762,629,000-2,073,224,000-794,901,000-1,227,990,000-815,021,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
URL
https://www.oncotherapy.co.jp/
IPO date
Dec 08, 2003
Employees
60
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT